Purification, characterization, structural analysis and protein chemistry of a buffalo heart galectin-1

Ashraf, Ghulam Md; Rizvi, Sabika; Naqvi, Shoa; Suhail, Nida; Bilal, Nayeem; Hasan, Shirin; Tabish, Mohammad; Banu, Naheed

doi:10.1007/s00726-010-0574-7

Cited by 19 publications

(6 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The GHG-1 was isolated and purified in essence according to our previously published studies on heart lectins (Ashraf et al, 2010a,b, 2011). Protein concentration was estimated by Lowry et al (1951) and its activity was determined by hemagglutination activity using trypsinized rabbit erythrocytes by two fold serial dilutions on a microtiter V-shaped plate (Laxbro, India) (Raz and Lotan, 1981).…”

Section: Methodsmentioning

confidence: 99%

Studies on the role of goat heart galectin-1 as an erythrocyte membrane perturbing agent

Ashraf

Perveen

Zaidi

et al. 2015

Saudi Journal of Biological Sciences

Self Cite

View full text Add to dashboard Cite

Galectins are β-galactoside binding lectins with a potential hemolytic role on erythrocyte membrane integrity and permeability. In the present study, goat heart galectin-1 (GHG-1) was purified and investigated for its hemolytic actions on erythrocyte membrane. When exposed to various saccharides, lactose and sucrose provided maximum protection against hemolysis, while glucose and galactose provided lesser protection against hemolysis. GHG-1 agglutinated erythrocytes were found to be significantly hemolyzed in comparison with unagglutinated erythrocytes. A concentration dependent rise in the hemolysis of trypsinized rabbit erythrocytes was observed in the presence of GHG-1. Similarly, a temperature dependent gradual increase in percent hemolysis was observed in GHG-1 agglutinated erythrocytes as compared to negligible hemolysis in unagglutinated cells. The hemolysis of GHG-1 treated erythrocytes showed a sharp rise with the increasing pH up to 7.5 which became constant till pH 9.5. The extent of erythrocyte hemolysis increased with the increase in the incubation period, with maximum hemolysis after 5 h of incubation. The results of this study establish the ability of galectins as a potential hemolytic agent of erythrocyte membrane, which in turn opens an interesting avenue in the field of proteomics and glycobiology.

show abstract

Section: Methodsmentioning

confidence: 99%

Studies on the role of goat heart galectin-1 as an erythrocyte membrane perturbing agent

Ashraf

Perveen

Zaidi

et al. 2015

Saudi Journal of Biological Sciences

Self Cite

View full text Add to dashboard Cite

show abstract

“…Gal-1 is expressed in the normal heart of many species [ 22 – 24 ]. Cardiomyocytes constitutively express Gal-1 at the cytosolic compartment in an organized striated pattern close to sarcomeric actin but not myosin [ 23 ] ( Figure 1(a) ).…”

Section: Introductionmentioning

confidence: 99%

Galectin-1 as an Emerging Mediator of Cardiovascular Inflammation: Mechanisms and Therapeutic Opportunities

Seropián

Gónzalez

Maller

et al. 2018

Mediators of Inflammation

View full text Add to dashboard Cite

Galectin-1 (Gal-1), an evolutionarily conserved β-galactoside-binding lectin, controls immune cell homeostasis and tempers acute and chronic inflammation by blunting proinflammatory cytokine synthesis, engaging T-cell apoptotic programs, promoting expansion of T regulatory (Treg) cells, and deactivating antigen-presenting cells. In addition, this lectin promotes angiogenesis by co-opting the vascular endothelial growth factor receptor (VEGFR) 2 signaling pathway. Since a coordinated network of immunomodulatory and proangiogenic mediators controls cardiac homeostasis, this lectin has been proposed to play a key hierarchical role in cardiac pathophysiology via glycan-dependent regulation of inflammatory responses. Here, we discuss the emerging roles of Gal-1 in cardiovascular diseases including acute myocardial infarction, heart failure, Chagas cardiomyopathy, pulmonary hypertension, and ischemic stroke, highlighting underlying anti-inflammatory mechanisms and therapeutic opportunities. Whereas Gal-1 administration emerges as a potential novel treatment option in acute myocardial infarction and ischemic stroke, Gal-1 blockade may contribute to attenuate pulmonary arterial hypertension.

show abstract

“…Gal-3 is present in intracellular (cytosol and nucleus) as well as extracellular spaces, and has been reported to be expressed by almost all cell types ( Hasan et al, 2007 ; Fortuna-Costa et al, 2014 ). Gal-3 being a multifunctional protein has been reported to be involved in plethora of physiological functions like immune activation, apoptosis, angiogenesis and fibrosis, which in turn have been intricately associated with the development and progression of various NDDs ( Ashraf et al, 2010b , 2011 ; Radosavljevic et al, 2012 ; Tam and Pasternak, 2012 ). Gal-3 has also been reported to inhibit the peripheral nerve generation post axotomy ( Narciso et al, 2009 ; DeFrancesco-Lisowitz et al, 2015 ), act as cell surface receptor for AGEs ( Yamamoto and Yamamoto, 2012 ; Chen H. et al, 2017 ), and exacerbate the CNS damage in experimental autoimmune encephalomyelitis (EAE) ( Jiang et al, 2009 ; de Oliveira et al, 2015 ).…”

Section: Introductionmentioning

confidence: 99%

Investigation of Gal-3 Expression Pattern in Serum and Cerebrospinal Fluid of Patients Suffering From Neurodegenerative Disorders

Ashraf

Baeesa

2018

Front. Neurosci.

View full text Add to dashboard Cite

We performed this study to investigate the possibility of a definitive pattern of Galectin-3 (Gal-3) expression in the cerebrospinal fluid (CSF) and serum of Alzheimer’s disease (AD) and Amyotrophic Lateral Sclerosis (ALS) patients. In our study, we collected the CSF and serum samples of 31 AD patients, 19 ALS patients and 50 normal healthy subjects (controls). Quantitative ELISA measured Gal-3 concentrations in CSF and serum samples. A comparative analysis was performed to analyze and understand the Gal-3 expression pattern. A number of neuropsychological assessments and statistical analyses were carried out to validate our findings. Recent researches have established the role of galectins in various neurodegenerative disorders (NDDs), but a definitive pattern of galectin expression is still elusive. A significant difference was observed in serum and CSF Gal-3 concentrations between AD patients and healthy controls. The difference in serum and CSF Gal-3 concentrations between ALS patients vs. controls was lesser as compared to AD patients vs. controls. The difference in serum and CSF Gal-3 concentrations of AD vs. ALS patients was not significant. The MMSE score and serum and CSF Gal-3 concentrations in AD and ALS patients, and controls exhibited a significant positive correlation. The findings of the present study are expected to provide an insight into the definitive pattern of Gal-3 expression in AD and ALS patients, and might thus establish Gal-3 as a strong biomarker. This in turn will open up new and promising research avenues targeting the expression of galectins to modulate the progression of NDDs, and pave the way for novel therapeutic options.

show abstract

Purification, characterization, structural analysis and protein chemistry of a buffalo heart galectin-1

Cited by 19 publications

References 32 publications

Studies on the role of goat heart galectin-1 as an erythrocyte membrane perturbing agent

Studies on the role of goat heart galectin-1 as an erythrocyte membrane perturbing agent

Galectin-1 as an Emerging Mediator of Cardiovascular Inflammation: Mechanisms and Therapeutic Opportunities

Investigation of Gal-3 Expression Pattern in Serum and Cerebrospinal Fluid of Patients Suffering From Neurodegenerative Disorders

Contact Info

Product

Resources

About